Bacteriostatic and bactericidal in-vitro activity of meropenem against clinical isolates, including Mycobacterium avium complex
Clark B. Inderlied, Mariselle G. Lancero, L. S. Young
Abstract
Clark B. Inderlied, Mariselle G. Lancero, L. S. Young
Abstract
For clinical isolates the MICs of meropenem were significantly lower than the MICs of imipenem, especially against Pseudomonas aeruginosa. Furthermore, meropenem was bactericidal for Pseudomonas spp., including Ps. (Xanthomonas) maltophilia, and staphylococci, with MBCs on average only two-fold above the respective MICs. The bactericidal activity was confirmed by killing curve assays. Strains with high meropenem MICs (greater than or equal to 8 mg/l) were killed by a combination of the carbapenem and amikacin, with kinetics that indicated synergism between the two antimicrobial agents.
OpenAlex reports 16 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
For clinical isolates the MICs of meropenem were significantly lower than the MICs of imipenem, especially against Pseudomonas aeruginosa. Furthermore, meropenem was bactericidal for Pseudomonas spp., including Ps. (Xanthomonas) maltophilia, and staphylococci, with MBCs on average only two-fold above the respective MICs. The bactericidal activity was confirmed by killing curve assays. Strains with high meropenem MICs (greater than or equal to 8 mg/l) were killed by a combination of the carbapenem and amikacin, with kinetics that indicated synergism between the two antimicrobial agents.
Key concepts: Meropenem, Microbiology, Imipenem, Pseudomonas aeruginosa, Amikacin, Antimicrobial, Antibacterial agent, Carbapenem